Recombinant pox virus for immunization against MUC1 tumor-associated antigen

A pharmaceutical composition comprising a recombinant pox virus comprising a nucleic acid sequence encoding an immunogenic MUC1 fragment comprising 5 to 25 MUC1 tandem repeat units, the nucleic acid sequence comprising

• a first nucleotide sequence encoding the amino acid sequence of SEQ ID NO:1 that is SEQ ID NO:2;
• a second nucleotide sequence encoding 2 to 24 copies of the amino acid sequence of SEQ ID NO:1 wherein, the second nucleotide sequence comprising 2 to 24 copies of an altered nucleotide sequence of SEQ ID NO:2 is altered by changing wobbled nucleotides of the codons of SEQ ID NO:2;
• and
• a third nucleotide sequence encoding an immunomodulator.

A recombinant pox virus comprising a nucleic acid sequence encoding an immunogenic MUC1 fragment comprising 5 to 25 MUC1 tandem repeat units, the nucleic acid sequence comprising

• a first nucleotide sequence having SEQ ID NO:2;
• and
• a second nucleotide sequence comprising 2 to 24 altered nucleotide sequences encoding 2 to 24 altered tandem repeats, wherein each altered tandem repeat is altered from SEQ ID NO:2 by changing at least one nucleotide of at least one codon of SEQ ID NO:
• 2 so that the amino acid of SEQ ID NO:
• 1 is maintained or by substituting at least one codon in SEQ ID NO:1 such that such substituted codons is selected from the group consisting of substituting at least one of the glycines in the SEQ ID NO:1 to serine, substituting at least one of the serines in the SEQ ID NO:1 to glycine, and substituting the valine in the SEQ ID NO:1 to leucine.